Ocular adverse effects of COVID-19 vaccines : A systematic review
Copyright: © 2022 Journal of Family Medicine and Primary Care..
The COVID-19 pandemic has led to the development and rollout of several vaccines worldwide at unprecedented pace. This systematic review of published literature has been undertaken to spread awareness among general physicians and ophthalmologists about the various reported adverse effects in the eye following COVID-19 vaccination. A systematic search was performed on 25 January 2022 through PuBMed, Medline and Google scholar for publications on ocular adverse effects after COVID-19 vaccination. One brief communication, four retrospective case series, sixteen case reports, and five letters to editors were included. Ocular manifestations most commonly appear in the uvea and retina. Other manifestations are seen on the eyelid, cornea and ocular surface, and in cranial nerves innervating the eye. The incidence rate of these manifestations is quite low after COVID-19 vaccinations. Our systematic review meticulously enumerates various adverse effects of COVID -19 vaccine on the eye. Most of these adverse effects are transient and observed to resolve without any sequelae except for cases of retinal and ophthalmic vascular occlusions and corneal graft rejections. An emphasis on close follow-up and a need to delay vaccination and modified therapy to control flare up of signs and symptoms in certain sub-populations, Graves' disease (autoimmune etiology), pre-existing uveal inflammation and corneal graft cases are warranted. We need long-term, larger, multicentric studies to substantiate our findings and establish the causal relationship with certainty. Mass vaccinations to curb this pandemic after outweighing the ocular risks associated with it is warranted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of family medicine and primary care - 11(2022), 9 vom: 20. Sept., Seite 5041-5054 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kumari, Shalini [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 21.12.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4103/jfmpc.jfmpc_747_22 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350177589 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350177589 | ||
| 003 | DE-627 | ||
| 005 | 20231226044413.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/jfmpc.jfmpc_747_22 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM350177589 | ||
| 035 | |a (NLM)36505575 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kumari, Shalini |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ocular adverse effects of COVID-19 vaccines |b A systematic review |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © 2022 Journal of Family Medicine and Primary Care. | ||
| 520 | |a The COVID-19 pandemic has led to the development and rollout of several vaccines worldwide at unprecedented pace. This systematic review of published literature has been undertaken to spread awareness among general physicians and ophthalmologists about the various reported adverse effects in the eye following COVID-19 vaccination. A systematic search was performed on 25 January 2022 through PuBMed, Medline and Google scholar for publications on ocular adverse effects after COVID-19 vaccination. One brief communication, four retrospective case series, sixteen case reports, and five letters to editors were included. Ocular manifestations most commonly appear in the uvea and retina. Other manifestations are seen on the eyelid, cornea and ocular surface, and in cranial nerves innervating the eye. The incidence rate of these manifestations is quite low after COVID-19 vaccinations. Our systematic review meticulously enumerates various adverse effects of COVID -19 vaccine on the eye. Most of these adverse effects are transient and observed to resolve without any sequelae except for cases of retinal and ophthalmic vascular occlusions and corneal graft rejections. An emphasis on close follow-up and a need to delay vaccination and modified therapy to control flare up of signs and symptoms in certain sub-populations, Graves' disease (autoimmune etiology), pre-existing uveal inflammation and corneal graft cases are warranted. We need long-term, larger, multicentric studies to substantiate our findings and establish the causal relationship with certainty. Mass vaccinations to curb this pandemic after outweighing the ocular risks associated with it is warranted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cornea | |
| 650 | 4 | |a SARS-COV-2 | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a eye | |
| 650 | 4 | |a eyelid | |
| 650 | 4 | |a neuropathy | |
| 650 | 4 | |a ocular adverse effects | |
| 650 | 4 | |a retinopathy | |
| 650 | 4 | |a uvea | |
| 650 | 4 | |a vaccination | |
| 700 | 1 | |a Anand, Raj |e verfasserin |4 aut | |
| 700 | 1 | |a Sambyal, Bhumika |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Yudhyavir |e verfasserin |4 aut | |
| 700 | 1 | |a Rangappa, Pradeep |e verfasserin |4 aut | |
| 700 | 1 | |a Jha, Simant Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of family medicine and primary care |d 2012 |g 11(2022), 9 vom: 20. Sept., Seite 5041-5054 |w (DE-627)NLM23498807X |x 2249-4863 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:9 |g day:20 |g month:09 |g pages:5041-5054 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/jfmpc.jfmpc_747_22 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 9 |b 20 |c 09 |h 5041-5054 | ||